Additionally, treatment with benzalutamide (BEN) increases the release of BRN4 (Brain4) and BRN2 (Brain2) in extracellular vesicles (EVs) derived from PCa cells, promoting the progression of NEPC [42]. Here, POU3F4 is linked to posterior cortical atrophy.